Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Declines By 18.4%

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 681,400 shares, a decline of 18.4% from the November 30th total of 835,500 shares. Based on an average daily trading volume, of 190,300 shares, the short-interest ratio is presently 3.6 days. Approximately 3.5% of the company’s shares are sold short.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded down $0.01 during trading on Friday, reaching $1.65. The company had a trading volume of 202,764 shares, compared to its average volume of 244,499. Vigil Neuroscience has a twelve month low of $1.54 and a twelve month high of $6.06. The firm has a market capitalization of $67.45 million, a PE ratio of -0.80 and a beta of 1.65. The firm’s fifty day moving average is $2.80 and its 200 day moving average is $3.41.

Wall Street Analysts Forecast Growth

VIGL has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday, November 8th. Wedbush boosted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, William Blair started coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience has an average rating of “Buy” and a consensus target price of $19.75.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in shares of Vigil Neuroscience in the 2nd quarter worth $5,940,000. abrdn plc acquired a new position in Vigil Neuroscience during the third quarter worth about $799,000. Ensign Peak Advisors Inc raised its position in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares in the last quarter. Verition Fund Management LLC acquired a new stake in Vigil Neuroscience in the 3rd quarter valued at about $442,000. Finally, Walleye Capital LLC boosted its position in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.